BioRem Statistics
Total Valuation
BioRem has a market cap or net worth of CAD 42.55 million. The enterprise value is 37.28 million.
| Market Cap | 42.55M |
| Enterprise Value | 37.28M |
Important Dates
The next estimated earnings date is Friday, March 20, 2026.
| Earnings Date | Mar 20, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BioRem has 16.12 million shares outstanding. The number of shares has decreased by -3.61% in one year.
| Current Share Class | 16.12M |
| Shares Outstanding | 16.12M |
| Shares Change (YoY) | -3.61% |
| Shares Change (QoQ) | +0.13% |
| Owned by Insiders (%) | 2.00% |
| Owned by Institutions (%) | n/a |
| Float | 15.79M |
Valuation Ratios
The trailing PE ratio is 26.73 and the forward PE ratio is 10.15.
| PE Ratio | 26.73 |
| Forward PE | 10.15 |
| PS Ratio | 1.23 |
| PB Ratio | 3.49 |
| P/TBV Ratio | 3.49 |
| P/FCF Ratio | 19.12 |
| P/OCF Ratio | 16.55 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 10.21, with an EV/FCF ratio of 16.75.
| EV / Earnings | 17.67 |
| EV / Sales | 1.07 |
| EV / EBITDA | 10.21 |
| EV / EBIT | 11.89 |
| EV / FCF | 16.75 |
Financial Position
The company has a current ratio of 1.89, with a Debt / Equity ratio of 0.25.
| Current Ratio | 1.89 |
| Quick Ratio | 1.56 |
| Debt / Equity | 0.25 |
| Debt / EBITDA | 0.84 |
| Debt / FCF | 1.39 |
| Interest Coverage | 18.58 |
Financial Efficiency
Return on equity (ROE) is 19.05% and return on invested capital (ROIC) is 13.53%.
| Return on Equity (ROE) | 19.05% |
| Return on Assets (ROA) | 7.52% |
| Return on Invested Capital (ROIC) | 13.53% |
| Return on Capital Employed (ROCE) | 21.47% |
| Revenue Per Employee | 1.02M |
| Profits Per Employee | 62,064 |
| Employee Count | 34 |
| Asset Turnover | 1.33 |
| Inventory Turnover | 10.47 |
Taxes
In the past 12 months, BioRem has paid 768,169 in taxes.
| Income Tax | 768,169 |
| Effective Tax Rate | 26.69% |
Stock Price Statistics
The stock price has decreased by -15.38% in the last 52 weeks. The beta is 0.59, so BioRem's price volatility has been lower than the market average.
| Beta (5Y) | 0.59 |
| 52-Week Price Change | -15.38% |
| 50-Day Moving Average | 2.29 |
| 200-Day Moving Average | 2.17 |
| Relative Strength Index (RSI) | 60.73 |
| Average Volume (20 Days) | 29,034 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BioRem had revenue of CAD 34.73 million and earned 2.11 million in profits. Earnings per share was 0.10.
| Revenue | 34.73M |
| Gross Profit | 8.42M |
| Operating Income | 3.14M |
| Pretax Income | 2.88M |
| Net Income | 2.11M |
| EBITDA | 3.46M |
| EBIT | 3.14M |
| Earnings Per Share (EPS) | 0.10 |
Balance Sheet
The company has 8.35 million in cash and 3.08 million in debt, giving a net cash position of 5.27 million or 0.33 per share.
| Cash & Cash Equivalents | 8.35M |
| Total Debt | 3.08M |
| Net Cash | 5.27M |
| Net Cash Per Share | 0.33 |
| Equity (Book Value) | 12.20M |
| Book Value Per Share | 0.76 |
| Working Capital | 11.69M |
Cash Flow
In the last 12 months, operating cash flow was 2.57 million and capital expenditures -344,798, giving a free cash flow of 2.23 million.
| Operating Cash Flow | 2.57M |
| Capital Expenditures | -344,798 |
| Free Cash Flow | 2.23M |
| FCF Per Share | 0.14 |
Margins
Gross margin is 24.25%, with operating and profit margins of 9.03% and 6.08%.
| Gross Margin | 24.25% |
| Operating Margin | 9.03% |
| Pretax Margin | 8.29% |
| Profit Margin | 6.08% |
| EBITDA Margin | 9.96% |
| EBIT Margin | 9.03% |
| FCF Margin | 6.41% |
Dividends & Yields
BioRem does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 3.61% |
| Shareholder Yield | 3.61% |
| Earnings Yield | 4.96% |
| FCF Yield | 5.23% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BioRem has an Altman Z-Score of 3.77 and a Piotroski F-Score of 5.
| Altman Z-Score | 3.77 |
| Piotroski F-Score | 5 |